India using Kashmir to oppose Silk Road project: Chinese media

March 30, 2017

Beijing, Mar 30: India sees China's Silk Road initiative as a geopolitical competition and is using the Kashmir issue as an "unfounded excuse" to oppose the ambitious project, Chinese state media today alleged and asked New Delhi to "abandon" its "cliche mentality".

"The official reason the Indian government rejected the offer to join the initiative (Silk Road) is that it is designed to pass through Kashmir. However, it is just an unfounded excuse as Beijing has been maintaining a consistent position on the Kashmir issue, which has never changed," one of the two articles on India by state-run Global Times said.

China1"India sees the Belt and Road initiative as a geopolitical competition," the article said, criticising India for hindering Beijing's push into South Asia and the world with multi-billion Silk Road project which is also known as the 'Belt and Road' (BR).

"Whether to continue to boycott or join the Belt and Road remains a conundrum for New Delhi," it said adding that, India is the only one which can help itself. The article said that India should give up its "biased" view on the BR initiative. "It is high time to abandon the cliche mentality of associating everything with geopolitics.

India will surely see a different world if it does," the article said. Referring to India's reservations to attend the BR summit called by Chinese President Xi Jinping, the article said it may be an "embarrassing occasion" for India as the meeting is backed by "China's peripheral countries, notably Russia, Indonesia, Kazakhstan and Pakistan".

Chinese Foreign Minister Wang Yi recently said 20 heads of state will attend the summit, together with over 50 leaders from international organisations, over 100 ministerial officials and more than 1,200 guests from around the world.

The article referred to a comment by Foreign Secretary S Jaishankar during his visit here last month to co-chair the upgraded India-China strategic dialogue, saying India is examining China's invitation to attend the summit and "how a country whose sovereignty has been violated can come on aninvitation".

In the meantime, however, state-run Chinese media stepped up campaign to pressurise India to join the summit. China apparently is keen about India's participation in the summit as the project struggled to make headway in the region except the USD 46 billion China Pakistan Economic Corridor (CPEC) where both Beijing-Islamabad are putting all efforts to show early harvest.

Media reports here said that Xi plans to invite his US counterpart Donald Trump to attend the meeting during their first summit early next month in Florida. BR consisted of maze of roads, including CPEC, Bangladesh-China-India-Myanmar Economic (BCIM) Corridor and 21st Maritime Silk Road besides road network to connect China with Eurasia.

The article also said, "it seems that the mainstream opinion throughout India is that the connectivity brought about by BR initiative is geopolitically significant. Therefore, India cannot allow the initiative to expand further into South Asia".

"This could also explain why the BCIM has seen no progress since its proposed by Chinese Premier Li Keqiang in 2013, and also why New Delhi has been keen on Japan's investment in the Iranian port of Chabahar," it said.

"New Delhi may also feel embarrassed as Moscow has actively responded to the Belt and Road initiative and will build an economic corridor with China and Mongolia," it said, adding Russia and Iran seeking to join the CPEC putting "India in a more awkward position".

It said, "Beijing has expressed, on various occasions, its anticipation to see New Delhi join the grand project and to make concerted effort with India in building economic corridors involving China, India, Sri Lanka, Nepal, Bangladesh and Myanmar".

Another article in the same daily said a "benign" competition between India and China may help development in South Asia but they should avoid "cut-throat" rivalry. "The so-called dragon-elephant contention is perhaps a blow against strategic mutual trust between Beijing and New Delhi, but may be conducive to development in South Asia," it said.

Accusing India of not being "generous" to its neighbours, it said "a yawning infrastructure funding gap in South Asian countries creates space for China and those nations to strengthen economic cooperation".

"Bangladesh and China signed 27 deals worth billions of dollars during President Xi Jinping's visit last year," it said, adding China's BR initiative has received an increasing amount of attention from Bangladesh.

"Only by investing more resources in regional integration and extending the benefits from India's rapid economic growth to other South Asian countries can New Delhi maintain its influence in the region," it said.

"Benign competition between China and India will be conducive to development in South Asia. The question remaining is how to avoid cut-throat competition as Beijing and New Delhi jostle for influence. India and China should seek common ground while strengthening cooperation with South Asian countries to promote regional integration," it said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

Manila, Aug 2: The number of COVID-19 cases in the Philippines has exceeded the 100,000 marks with a record 5,032 new infections registered on Sunday, the Health Ministry's data showed.

With the total cases now reaching 103,185, the spread of COVID-19 in the Southeast Asian nation is steeply rising. The daily growth rate just this Thursday set a record at over 3,800 cases, the next day there were nearly 4,000 new infections detected and on Saturday, over 4,800 cases were detected.

More than 65,000 people have recovered from the ailment, while 2,059 people have died.

The Philippines' epidemiological dynamic mirrors that of many Southeast Asian nations, where COVID-19 infections have only recently begun to climb. 

Most other nations in Europe and the Americas experienced an initial spread of the virus which later tailed off only to begin climbing again after easing of restrictions.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 4,2020

Washington D.C, Jun 4: A lawsuit has been filed against US President Donald Trump for signing an executive order on preventing online censorship that seems to violate the freedom of speech of individuals on social media platforms.

On Tuesday, the Center for Democracy and Technology filed the lawsuit against Trump's "Executive Order on Preventing Online Censorship," which was signed May 28, 2020. The suit argues that the Executive Order violates the First Amendment by curtailing and chilling the constitutionally protected speech of online platforms and individuals.

"CDT filed suit today because the President's actions are a direct attack on the freedom of speech protected by the First Amendment. The government cannot and should not force online intermediaries into moderating speech according to the President's whims. Blocking this order is crucial for protecting freedom of speech and continuing important work to ensure the integrity of the 2020 election," said CDT President and CEO Alexandra Givens.

The executive order is designed to deter social media services from fighting misinformation, voter suppression, and the stoking of violence on their platforms, the digital rights group said.

"Access to accurate information about the voting process and the security of our elections infrastructure is the lifeblood of our democracy. The President has made clear that his goal is to use threats of retaliation and future regulation to intimidate intermediaries into changing how they moderate content, essentially ensuring that the dangers of voter suppression and disinformation will grow unchecked in an election year," Givens said.

The law firm of Mayer Brown is representing CDT in this action.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.